董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph C. Galante | 男 | Director | 71 | 5.36万美元 | 未持股 | 2021-03-15 |
| Caroline R. Young | 女 | Director | 46 | 6.11万美元 | 未持股 | 2021-03-15 |
| Kenneth J. Krogulski | 男 | Director | 63 | 6.11万美元 | 未持股 | 2021-03-15 |
| Joey Jacobs | 男 | Director | 67 | 7.78万美元 | 未持股 | 2021-03-15 |
| Jonathan Griggs | 男 | Director | 86 | 6.36万美元 | 未持股 | 2021-03-15 |
| James R. Jones | 男 | Director | 73 | 6.36万美元 | 未持股 | 2021-03-15 |
| A.J. Kazimi | 男 | Director, Chairman of the Board and Chief Executive Officer | 62 | 115.55万美元 | 未持股 | 2021-03-15 |
| Martin E. Cearnal | 男 | Director, Executive Vice President and Chief Commercial Officer | 76 | 40.95万美元 | 未持股 | 2021-03-15 |
| Gordon R. Bernard | 男 | Director | 69 | 9.80万美元 | 未持股 | 2021-03-15 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph C. Galante | 男 | Director | 71 | 5.36万美元 | 未持股 | 2021-03-15 |
| Michael P. Bonner | 男 | Senior Director Accounting & Finance and Chief Financial Officer | 44 | 25.57万美元 | 未持股 | 2021-03-15 |
| Caroline R. Young | 女 | Director | 46 | 6.11万美元 | 未持股 | 2021-03-15 |
| Kenneth J. Krogulski | 男 | Director | 63 | 6.11万美元 | 未持股 | 2021-03-15 |
| Leo B. Pavliv | 男 | Executive Vice President, Operations and Chief Development Officer | 60 | 未披露 | 未持股 | 2021-03-15 |
| Joey Jacobs | 男 | Director | 67 | 7.78万美元 | 未持股 | 2021-03-15 |
| Jonathan Griggs | 男 | Director | 86 | 6.36万美元 | 未持股 | 2021-03-15 |
| James R. Jones | 男 | Director | 73 | 6.36万美元 | 未持股 | 2021-03-15 |
| A.J. Kazimi | 男 | Director, Chairman of the Board and Chief Executive Officer | 62 | 115.55万美元 | 未持股 | 2021-03-15 |
| Martin E. Cearnal | 男 | Director, Executive Vice President and Chief Commercial Officer | 76 | 40.95万美元 | 未持股 | 2021-03-15 |
| Gordon R. Bernard | 男 | Director | 69 | 9.80万美元 | 未持股 | 2021-03-15 |
| Leo Pavliv | 男 | Executive Vice President, Operations and Chief Development Officer | 60 | 57.92万美元 | 未持股 | 2021-03-15 |
| James L. Herman | 男 | Senior Vice President and Chief Compliance Officer | 64 | 33.24万美元 | 未持股 | 2021-03-15 |
董事简历
中英对照 |  中文 |  英文- Joseph C. Galante
-
Joseph C. Galante从1995年1月直到2010年7月退休担任索尼音乐(Sony Music)的董事会主席。他帮助阿拉巴马、柯林布雷克、肯尼·切斯尼、萨拉·埃文斯、戴夫·马休斯、武当派、SWV、贾德氏、孤星合唱团、玛蒂娜·麦克布莱德、K.T. Oslin、凯丽·皮克勒、凯莉·安德伍德、凯斯惠特利、克里斯杨和众多其他歌手开启演艺事业。他的领导力为诸如布鲁克斯和邓恩组合、艾伦·杰克逊、米兰达·兰伯特和布拉德·派斯利等超级明星的演艺事业提供了支撑。他担任美国乡村音乐协会(Country Music Association)、易洛魁资本(Iroquois Capital)、Artist Growth和Fishbowl Spirits的董事。他目前担任纳什维尔企业家中心的常驻导师。
Joseph C. Galante has served as a member of our Board of Directors since 2018. Mr. Galante is a music industry executive with extensive experience that scans a celebrated career. He is accredited with developing the careers of Alabama, Dave Mathews Band, Dolly Parton, Kenny Chesney, Brad Paisley, Martina McBride, Carrie Underwood, Clint Black, Miranda Lambert, and the Judds, among others. Mr. Galante began at RCA Records in New York, followed by a transfer to RCA Nashville where he served as a director at the label, followed by the role of Vice President of Promotion and Marketing. At the age of 32 he became the youngest person ever named to run a major country record label. In 1990 he was appointed President of RCA Records US based in New York. He returned to Nashville as Chairman to run the RCA and BNA labels in Nashville. Under his leadership, RCA Records was the number one country label for eleven consecutive years. He then served as Chairman of Sony Music Nashville for six years. He was presented with the Bob Kingsley Living Legend Award by the Opry Trust to honor his work for country music. Mr. Galante is currently a member of the Board of Directors of Pinnacle Financial Partners whose shares are listed on the Nasdaq stock exchange, the Country Music Association, and serves as the Chair of the CMA Foundation. - Joseph C. Galante从1995年1月直到2010年7月退休担任索尼音乐(Sony Music)的董事会主席。他帮助阿拉巴马、柯林布雷克、肯尼·切斯尼、萨拉·埃文斯、戴夫·马休斯、武当派、SWV、贾德氏、孤星合唱团、玛蒂娜·麦克布莱德、K.T. Oslin、凯丽·皮克勒、凯莉·安德伍德、凯斯惠特利、克里斯杨和众多其他歌手开启演艺事业。他的领导力为诸如布鲁克斯和邓恩组合、艾伦·杰克逊、米兰达·兰伯特和布拉德·派斯利等超级明星的演艺事业提供了支撑。他担任美国乡村音乐协会(Country Music Association)、易洛魁资本(Iroquois Capital)、Artist Growth和Fishbowl Spirits的董事。他目前担任纳什维尔企业家中心的常驻导师。
- Joseph C. Galante has served as a member of our Board of Directors since 2018. Mr. Galante is a music industry executive with extensive experience that scans a celebrated career. He is accredited with developing the careers of Alabama, Dave Mathews Band, Dolly Parton, Kenny Chesney, Brad Paisley, Martina McBride, Carrie Underwood, Clint Black, Miranda Lambert, and the Judds, among others. Mr. Galante began at RCA Records in New York, followed by a transfer to RCA Nashville where he served as a director at the label, followed by the role of Vice President of Promotion and Marketing. At the age of 32 he became the youngest person ever named to run a major country record label. In 1990 he was appointed President of RCA Records US based in New York. He returned to Nashville as Chairman to run the RCA and BNA labels in Nashville. Under his leadership, RCA Records was the number one country label for eleven consecutive years. He then served as Chairman of Sony Music Nashville for six years. He was presented with the Bob Kingsley Living Legend Award by the Opry Trust to honor his work for country music. Mr. Galante is currently a member of the Board of Directors of Pinnacle Financial Partners whose shares are listed on the Nasdaq stock exchange, the Country Music Association, and serves as the Chair of the CMA Foundation.
- Caroline R. Young
-
CarolineR.Young于2016年加入坎伯兰药业董事会。她此前曾担任the Nashville Health Care Council的总裁(从2008年到2015年)。在她的领导下,该委员会的成员已扩大到300多个不同的组织,并发起了一项旨在提高企业高管技能的独一无二的研究员计划。此外,该委员会的创新领导力医疗保健计划扩大到1000名成员。Young女士于2004年加入理事会,担任Vice President。在理事会之前,Young女士从2002年到2004年是Life Science Tennessee的创始执行董事。从1998年到2002年,她还担任田纳西州经济和社区发展部的通信职位。Young女士最近担任NashvilleHealth的执行董事,这是一项专注于改善Nashville-Davidson县公民健康的倡议。NashvilleHealth致力于解决地区健康平等问题,并确保Nashville继续成为一个很好的生活和工作场所。《纳什维尔商业日报》(Nashville Business Journal)和《纳什维尔医学新闻》(Nashville Medical News)分别将杨女士评为“梦百合英雄”和“值得关注的女性”。目前,杨女士是总部位于华盛顿特区的美国梦百合行业女性商界领袖顾问委员会的成员。Young女士拥有密西西比大学(University of Mississippi)的学士学位和田纳西大学(University of Tennessee)的硕士学位。
Caroline R. Young joined the Board of Directors of Cumberland Pharmaceuticals in 2016. Ms. Young was previously the President of the Nashville Health Care Council, a position she held from 2008 to 2015. Under her leadership, the Council’s membership grew to encompass 300 diverse organizations and launched the one-of-a-kind Fellows initiative designed to further the skills of business executives. Additionally, the Council’s innovative Leadership Health Care program expanded to consist of 1000 members. Ms. Young joined the Council in 2004 serving as vice president. Prior to the Council, Ms. Young was the founding Executive Director of Life Science Tennessee from 2002 to 2004. She also served in communications roles for the State of Tennessee’s Department of Economic and Community Development ECD from 1998 to 2002. Ms. Young most recently served as the Executive Director of NashvilleHealth, an initiative focused on improving the health of the citizens of Nashville-Davidson County. NashvilleHealth addresses area health equity issues and ensures Nashville continues to be a great place to live and work. Ms. Young has been recognized by the Nashville Business Journal as a “Healthcare Hero,” and the Nashville Medical News as a “Woman to Watch.” Currently, Ms. Young is a member of the Advisory Board of the Washington, DC-based Women Business Leaders of the U.S. Healthcare Industry. Ms. Young holds a B.A. from the University of Mississippi and a M.S. from the University of Tennessee. - CarolineR.Young于2016年加入坎伯兰药业董事会。她此前曾担任the Nashville Health Care Council的总裁(从2008年到2015年)。在她的领导下,该委员会的成员已扩大到300多个不同的组织,并发起了一项旨在提高企业高管技能的独一无二的研究员计划。此外,该委员会的创新领导力医疗保健计划扩大到1000名成员。Young女士于2004年加入理事会,担任Vice President。在理事会之前,Young女士从2002年到2004年是Life Science Tennessee的创始执行董事。从1998年到2002年,她还担任田纳西州经济和社区发展部的通信职位。Young女士最近担任NashvilleHealth的执行董事,这是一项专注于改善Nashville-Davidson县公民健康的倡议。NashvilleHealth致力于解决地区健康平等问题,并确保Nashville继续成为一个很好的生活和工作场所。《纳什维尔商业日报》(Nashville Business Journal)和《纳什维尔医学新闻》(Nashville Medical News)分别将杨女士评为“梦百合英雄”和“值得关注的女性”。目前,杨女士是总部位于华盛顿特区的美国梦百合行业女性商界领袖顾问委员会的成员。Young女士拥有密西西比大学(University of Mississippi)的学士学位和田纳西大学(University of Tennessee)的硕士学位。
- Caroline R. Young joined the Board of Directors of Cumberland Pharmaceuticals in 2016. Ms. Young was previously the President of the Nashville Health Care Council, a position she held from 2008 to 2015. Under her leadership, the Council’s membership grew to encompass 300 diverse organizations and launched the one-of-a-kind Fellows initiative designed to further the skills of business executives. Additionally, the Council’s innovative Leadership Health Care program expanded to consist of 1000 members. Ms. Young joined the Council in 2004 serving as vice president. Prior to the Council, Ms. Young was the founding Executive Director of Life Science Tennessee from 2002 to 2004. She also served in communications roles for the State of Tennessee’s Department of Economic and Community Development ECD from 1998 to 2002. Ms. Young most recently served as the Executive Director of NashvilleHealth, an initiative focused on improving the health of the citizens of Nashville-Davidson County. NashvilleHealth addresses area health equity issues and ensures Nashville continues to be a great place to live and work. Ms. Young has been recognized by the Nashville Business Journal as a “Healthcare Hero,” and the Nashville Medical News as a “Woman to Watch.” Currently, Ms. Young is a member of the Advisory Board of the Washington, DC-based Women Business Leaders of the U.S. Healthcare Industry. Ms. Young holds a B.A. from the University of Mississippi and a M.S. from the University of Tennessee.
- Kenneth J. Krogulski
-
KennethJ.Krogulski于2017年加入坎伯兰董事会。他拥有40年以上的证券分析和投资组合管理经验,目前担任Berkshire Asset Management,LLC的总裁兼首席执行官,以及公司的首席投资官。伯克希尔是一家拥有33年历史的独立证券交易委员会注册的宾夕法尼亚州投资咨询公司,在监管下拥有超过22亿美元的资产。在Berkshire之前,Krogulski先生于1979年在First Eastern Bank,N.A.(现为PNC Financial)开始了他的金融服务职业生涯,担任投资分析师和投资组合经理,在那里他晋升为信托部首席投资官。他随后于1990年加入Berkshire公司,随后领导管理层收购Legg Mason公司。在他的领导下,伯克希尔在监管下的资产从2006年的6亿美元增长到现在的超过22亿美元。目前,Krogulski先生任职于Allied Services Rehabilitation Hospital的董事会,是Landmark Community Bank LDKB:NASDAQ的董事。此前,他曾担任the Wyoming Valley Health Care System、the F.M.Kirby Center for the Performing Arts、the Luzerne Foundation和其他各种社区委员会的董事。Krogulski先生拥有宾夕法尼亚印第安纳大学(Indiana University of Pennsylvania)的金融学学士学位,并在威尔克斯大学(Wilkes University)获得工商管理硕士学位。此外,他持有特许金融分析师称号。
Kenneth J. Krogulski joined Cumberland’s Board of Directors in 2017. He has over 40 years of experience in security analysis and portfolio management and is currently the President and Chief Executive Officer of Berkshire Asset Management, LLC, as well as the company’s Chief Investment Officer. Berkshire is a 33-year-old independent SEC registered Pennsylvania based investment advisory firm with over $2.2 billion in assets under supervision. Prior to Berkshire, Mr. Krogulski began his career in financial services in 1979 at First Eastern Bank, N.A., now PNC Financial, as an investment analyst and portfolio manager, where he advanced to Chief Investment Officer of the Trust Department. He then joined Berkshire in 1990 and later led a management buy-out acquiring the company from Legg Mason. Under his leadership Berkshire’s assets under supervision have grown from $600 million in 2006 and are now over $2.2 billion. Currently Mr. Krogulski serves on the board of Allied Services Rehabilitation Hospital and is a Director of Landmark Community Bank LDKB: Nasdaq. Previously he served as the Director of the Wyoming Valley Health Care System, on the board of the F.M. Kirby Center for the Performing Arts, the Luzerne Foundation and on various other community boards. Mr. Krogulski holds a B.S. in finance from Indiana University of Pennsylvania and earned his M.B.A. from Wilkes University. In addition, he holds the Chartered Financial Analyst designation. - KennethJ.Krogulski于2017年加入坎伯兰董事会。他拥有40年以上的证券分析和投资组合管理经验,目前担任Berkshire Asset Management,LLC的总裁兼首席执行官,以及公司的首席投资官。伯克希尔是一家拥有33年历史的独立证券交易委员会注册的宾夕法尼亚州投资咨询公司,在监管下拥有超过22亿美元的资产。在Berkshire之前,Krogulski先生于1979年在First Eastern Bank,N.A.(现为PNC Financial)开始了他的金融服务职业生涯,担任投资分析师和投资组合经理,在那里他晋升为信托部首席投资官。他随后于1990年加入Berkshire公司,随后领导管理层收购Legg Mason公司。在他的领导下,伯克希尔在监管下的资产从2006年的6亿美元增长到现在的超过22亿美元。目前,Krogulski先生任职于Allied Services Rehabilitation Hospital的董事会,是Landmark Community Bank LDKB:NASDAQ的董事。此前,他曾担任the Wyoming Valley Health Care System、the F.M.Kirby Center for the Performing Arts、the Luzerne Foundation和其他各种社区委员会的董事。Krogulski先生拥有宾夕法尼亚印第安纳大学(Indiana University of Pennsylvania)的金融学学士学位,并在威尔克斯大学(Wilkes University)获得工商管理硕士学位。此外,他持有特许金融分析师称号。
- Kenneth J. Krogulski joined Cumberland’s Board of Directors in 2017. He has over 40 years of experience in security analysis and portfolio management and is currently the President and Chief Executive Officer of Berkshire Asset Management, LLC, as well as the company’s Chief Investment Officer. Berkshire is a 33-year-old independent SEC registered Pennsylvania based investment advisory firm with over $2.2 billion in assets under supervision. Prior to Berkshire, Mr. Krogulski began his career in financial services in 1979 at First Eastern Bank, N.A., now PNC Financial, as an investment analyst and portfolio manager, where he advanced to Chief Investment Officer of the Trust Department. He then joined Berkshire in 1990 and later led a management buy-out acquiring the company from Legg Mason. Under his leadership Berkshire’s assets under supervision have grown from $600 million in 2006 and are now over $2.2 billion. Currently Mr. Krogulski serves on the board of Allied Services Rehabilitation Hospital and is a Director of Landmark Community Bank LDKB: Nasdaq. Previously he served as the Director of the Wyoming Valley Health Care System, on the board of the F.M. Kirby Center for the Performing Arts, the Luzerne Foundation and on various other community boards. Mr. Krogulski holds a B.S. in finance from Indiana University of Pennsylvania and earned his M.B.A. from Wilkes University. In addition, he holds the Chartered Financial Analyst designation.
- Joey Jacobs
-
Joey Jacobs于2011年加盟Cumberland的董事会,并且是治理和提名委员会的成员。他在医疗业拥有超过35年的行业经验。目前担任Acadia医疗保健(一个快速成长的行为健康公司)的董事长兼首席执行官。 他是纳什维尔的Psychiatric Solutions, Inc.PSI的前任主席、总裁兼首席执行官,于1997年参与创办公司,在2010年公司出售给Universal Health Services之前,帮助公司发展成一个市值20亿美元的公司。在创办PSI之前,在Hospital Corporation of America HCA工作了21年,担任多个职位。除了担任纳什维尔卫生保健委员会的前任主席外,他也是美国医院联合会和精神病卫生系统全国协会的前任董事。目前,担任在范德比尔特的儿科医院Monroe Carel、AmSurg公司和心理健康管理的董事会成员。持有中田纳西州立大学的理学士学位。
Joey Jacobs joined Cumberland’s Board of Directors in 2011 and is Chairman of our Governance and Nominating Committee and Lead Independent Director. A healthcare veteran with more than 45 years of industry experience, Mr. Jacobs is the former Chairman and Chief Executive Officer of Acadia Healthcare, a rapidly growing behavioral health company. Mr. Jacobs is the former Chairman, President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. PSI, which he co-founded in 1997 and grew into a $2 billion behavioral healthcare system before the company’s sale to Universal Health Services in 2010. Prior to founding PSI, Mr. Jacobs spent 21 years at Hospital Corporation of America, or HCA, where he served in various capacities. In addition to serving as the former Chairman of the Nashville Health Care Council, he is also a past director of the Federation of American Hospitals, the National Association of Psychiatric Health Systems, Mental Health Management and Envision Corporation. He is currently a board member of the Monroe Carell, Jr. Children’s Hospital at Vanderbilt and Middle Tennesse State University. Mr. Jacobs holds a B.S. degree from Middle Tennessee State University. - Joey Jacobs于2011年加盟Cumberland的董事会,并且是治理和提名委员会的成员。他在医疗业拥有超过35年的行业经验。目前担任Acadia医疗保健(一个快速成长的行为健康公司)的董事长兼首席执行官。 他是纳什维尔的Psychiatric Solutions, Inc.PSI的前任主席、总裁兼首席执行官,于1997年参与创办公司,在2010年公司出售给Universal Health Services之前,帮助公司发展成一个市值20亿美元的公司。在创办PSI之前,在Hospital Corporation of America HCA工作了21年,担任多个职位。除了担任纳什维尔卫生保健委员会的前任主席外,他也是美国医院联合会和精神病卫生系统全国协会的前任董事。目前,担任在范德比尔特的儿科医院Monroe Carel、AmSurg公司和心理健康管理的董事会成员。持有中田纳西州立大学的理学士学位。
- Joey Jacobs joined Cumberland’s Board of Directors in 2011 and is Chairman of our Governance and Nominating Committee and Lead Independent Director. A healthcare veteran with more than 45 years of industry experience, Mr. Jacobs is the former Chairman and Chief Executive Officer of Acadia Healthcare, a rapidly growing behavioral health company. Mr. Jacobs is the former Chairman, President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. PSI, which he co-founded in 1997 and grew into a $2 billion behavioral healthcare system before the company’s sale to Universal Health Services in 2010. Prior to founding PSI, Mr. Jacobs spent 21 years at Hospital Corporation of America, or HCA, where he served in various capacities. In addition to serving as the former Chairman of the Nashville Health Care Council, he is also a past director of the Federation of American Hospitals, the National Association of Psychiatric Health Systems, Mental Health Management and Envision Corporation. He is currently a board member of the Monroe Carell, Jr. Children’s Hospital at Vanderbilt and Middle Tennesse State University. Mr. Jacobs holds a B.S. degree from Middle Tennessee State University.
- Jonathan Griggs
-
Jonathan Griggs自2010年以来担任本公司董事会的一员,是我们的审计、薪酬和治理与提名委员会的成员。他的职业生涯中,在制药和生物技术行业工作超过40年,包括许多国际经验。在Warner Lambert Corporation工作23年,担任许多要职,最高任职是人力资源副总裁。在此期间,成功的领导了三家医药企业整合成为当时最大的企业Parke Davis。从1992年至今,一直担任Griggs & Associates(管理和人力资源咨询公司,协助创业公司和提供周转情况下的危急援助)的首席执行官。在 AACA Antique Auto Club of America Museum(领先的交通博物馆)的成立过程中,提供领导和战略管理,曾担任董事长,现任董事。持有宾夕法尼亚州立大学的理学士学位和宾夕法尼亚大学沃顿商学院的管理硕士学位。他一直是Cumberland Pharmaceuticals的顾问。自1999年公司开始运作起,担任医药顾问委员会的成员。
Jonathan Griggs has served as a member of Cumberland Pharmaceuticals Inc.'s Board of Directors since 2010. Mr. Griggs has elected to retire at the end of this term and will not stand for re-election at the Annual Meeting. His career spans more than 41 years in the pharmaceutical and biotechnology industries and includes significant international experience. He spent 23 years at Warner Lambert Corporation in positions of increasing responsibility, culminating with his position as Vice President of Human Resources. During his tenure with Warner Lambert, he provided leadership for the successful integration of three pharmaceutical businesses into what became Parke Davis, the largest consolidation in the industry at that time. From 1992 to present he has been the CEO of Griggs & Associates, a management and human resources consulting firm assisting start-up companies and providing critical assistance in turnaround situations. Mr. Griggs also provided the leadership and strategic management for the formation and establishment of the AACA Antique Auto Club of America Museum, a leading transportation museum where he served as chairman and is currently a director. Mr. Griggs has his B.S. Degree from Penn State and attended the Wharton School of Management at the University of Pennsylvania. He has been an advisor to Cumberland Pharmaceuticals as a member of the company's Pharmaceutical Advisory Board since it began operations in 1999. - Jonathan Griggs自2010年以来担任本公司董事会的一员,是我们的审计、薪酬和治理与提名委员会的成员。他的职业生涯中,在制药和生物技术行业工作超过40年,包括许多国际经验。在Warner Lambert Corporation工作23年,担任许多要职,最高任职是人力资源副总裁。在此期间,成功的领导了三家医药企业整合成为当时最大的企业Parke Davis。从1992年至今,一直担任Griggs & Associates(管理和人力资源咨询公司,协助创业公司和提供周转情况下的危急援助)的首席执行官。在 AACA Antique Auto Club of America Museum(领先的交通博物馆)的成立过程中,提供领导和战略管理,曾担任董事长,现任董事。持有宾夕法尼亚州立大学的理学士学位和宾夕法尼亚大学沃顿商学院的管理硕士学位。他一直是Cumberland Pharmaceuticals的顾问。自1999年公司开始运作起,担任医药顾问委员会的成员。
- Jonathan Griggs has served as a member of Cumberland Pharmaceuticals Inc.'s Board of Directors since 2010. Mr. Griggs has elected to retire at the end of this term and will not stand for re-election at the Annual Meeting. His career spans more than 41 years in the pharmaceutical and biotechnology industries and includes significant international experience. He spent 23 years at Warner Lambert Corporation in positions of increasing responsibility, culminating with his position as Vice President of Human Resources. During his tenure with Warner Lambert, he provided leadership for the successful integration of three pharmaceutical businesses into what became Parke Davis, the largest consolidation in the industry at that time. From 1992 to present he has been the CEO of Griggs & Associates, a management and human resources consulting firm assisting start-up companies and providing critical assistance in turnaround situations. Mr. Griggs also provided the leadership and strategic management for the formation and establishment of the AACA Antique Auto Club of America Museum, a leading transportation museum where he served as chairman and is currently a director. Mr. Griggs has his B.S. Degree from Penn State and attended the Wharton School of Management at the University of Pennsylvania. He has been an advisor to Cumberland Pharmaceuticals as a member of the company's Pharmaceutical Advisory Board since it began operations in 1999.
- James R. Jones
-
James R. Jones自2010年起一直担任我们的董事会成员。在毕马威会计师事务所作为专业会计度过了35年的职业生涯,包括从1999年到2006年担任在田纳西州纳什维尔办公室的管理合伙人。他曾在毕马威担任各种职位,其中包括在杰克逊、密西西比、华盛顿特区和格林维尔、南卡罗来纳州的办公室。任职于毕马威会计师事务所期间,率领100多人向庞大客户群提供会计服务。2006年退休之后,曾担任顾问,并提供给多家公司各种咨询服务,包括管理长期护理机构的董事会和担任慈善机构的临时行政总裁。他是在范德堡大学欧文研究生院的一位兼职教师。目前,他是田纳西Argent Trust Company的董事和审核委员会委员。亦担任本公司审核委员会主席,和委员会的财务专家。持有密西西比学院的理学士学位和密西西比州立大学的工商管理硕士学位。
James R. Jones has served as a member of our Board of Directors since 2010 and is Chair of our Audit Committee. Mr. Jones’ 36 year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in various capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, D.C. and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an extensive client base. Following retirement in 2006 he has served as an advisor as well as provided various consulting services to several companies, including acting as liaison between management and the board of directors of a long-term care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committees of Argent Trust Company of Tennessee and Belmont University. Mr. Jones also serves as a member of our Audit Committee and is our Audit Committee financial expert. Mr. Jones holds a B.S. from Mississippi College and an M.B.A from Mississippi State University. - James R. Jones自2010年起一直担任我们的董事会成员。在毕马威会计师事务所作为专业会计度过了35年的职业生涯,包括从1999年到2006年担任在田纳西州纳什维尔办公室的管理合伙人。他曾在毕马威担任各种职位,其中包括在杰克逊、密西西比、华盛顿特区和格林维尔、南卡罗来纳州的办公室。任职于毕马威会计师事务所期间,率领100多人向庞大客户群提供会计服务。2006年退休之后,曾担任顾问,并提供给多家公司各种咨询服务,包括管理长期护理机构的董事会和担任慈善机构的临时行政总裁。他是在范德堡大学欧文研究生院的一位兼职教师。目前,他是田纳西Argent Trust Company的董事和审核委员会委员。亦担任本公司审核委员会主席,和委员会的财务专家。持有密西西比学院的理学士学位和密西西比州立大学的工商管理硕士学位。
- James R. Jones has served as a member of our Board of Directors since 2010 and is Chair of our Audit Committee. Mr. Jones’ 36 year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in various capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, D.C. and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an extensive client base. Following retirement in 2006 he has served as an advisor as well as provided various consulting services to several companies, including acting as liaison between management and the board of directors of a long-term care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committees of Argent Trust Company of Tennessee and Belmont University. Mr. Jones also serves as a member of our Audit Committee and is our Audit Committee financial expert. Mr. Jones holds a B.S. from Mississippi College and an M.B.A from Mississippi State University.
- A.J. Kazimi
-
A.J. Kazimi于1999年创办本公司。自成立以来,一直担任公司董事会主席及行政总裁。他的职业生涯包括在生物制药行业的25年。在加入本公司前,帮助创立Therapeutic Antibodies Inc.(一家国际生物制药公司),长达11年。作为总裁兼首席运营官,从公司的起步到首次公开募股,他为公司的增长做出了突出的贡献。 监督三个国家的业务,亲自参与公司的产品开发战略、批准、许可协议和超过1亿美元的股权和债务融资筹集。在这之前,曾在Brown-Forman公司担任一系列的管理职位,并帮助推出多款新产品。 曾服务于纳什维尔保健委员会(美国最大医疗保健公司的行业协会)和Aegis Toxicology Sciences公司(由联邦政府认证的法医毒物实验室)的董事会。他还担任CET的主席及行政总裁。持有巴黎圣母院的理学士学位和范德堡大学欧文研究生院的MBA管理学位。
A.J. Kazimi founded our company in 1999 and has served as the Chairman of our Board of Directors and Chief Executive Officer since inception. His career includes 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of the company's Acetadote and Caldolor brands, while also leading the acquisition of the Company's five other commercial products. He was responsible for Cumberland's initial public offering and listing on the Nasdaq stock exchange. He also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies. Prior to joining our company, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company's growth from its start-up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions and helping to launch several new products. Mr. Kazimi serves on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. He also serves on the Boards of the Tennessee Historical Society and the Gettysburg Foundation which partners with the National Park Service to preserve the historic military park. Mr. Kazimi is a member of the Board of Visitors at the Vanderbilt University Business School and the Visiting Committee at the Loyola University New Orleans' College of Business. He previously served on the board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors. He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt University Owen Graduate School of Management. - A.J. Kazimi于1999年创办本公司。自成立以来,一直担任公司董事会主席及行政总裁。他的职业生涯包括在生物制药行业的25年。在加入本公司前,帮助创立Therapeutic Antibodies Inc.(一家国际生物制药公司),长达11年。作为总裁兼首席运营官,从公司的起步到首次公开募股,他为公司的增长做出了突出的贡献。 监督三个国家的业务,亲自参与公司的产品开发战略、批准、许可协议和超过1亿美元的股权和债务融资筹集。在这之前,曾在Brown-Forman公司担任一系列的管理职位,并帮助推出多款新产品。 曾服务于纳什维尔保健委员会(美国最大医疗保健公司的行业协会)和Aegis Toxicology Sciences公司(由联邦政府认证的法医毒物实验室)的董事会。他还担任CET的主席及行政总裁。持有巴黎圣母院的理学士学位和范德堡大学欧文研究生院的MBA管理学位。
- A.J. Kazimi founded our company in 1999 and has served as the Chairman of our Board of Directors and Chief Executive Officer since inception. His career includes 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of the company's Acetadote and Caldolor brands, while also leading the acquisition of the Company's five other commercial products. He was responsible for Cumberland's initial public offering and listing on the Nasdaq stock exchange. He also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies. Prior to joining our company, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company's growth from its start-up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions and helping to launch several new products. Mr. Kazimi serves on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. He also serves on the Boards of the Tennessee Historical Society and the Gettysburg Foundation which partners with the National Park Service to preserve the historic military park. Mr. Kazimi is a member of the Board of Visitors at the Vanderbilt University Business School and the Visiting Committee at the Loyola University New Orleans' College of Business. He previously served on the board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors. He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt University Owen Graduate School of Management.
- Martin E. Cearnal
-
Martin E. Cearnal自2004年起一直担任我们的董事会成员。2008年他加入我们的管理团队,领导Cumberland的商业发展。目前担任高级副总裁兼首席商务官。他是Physicians World(1985至2000年在他任职期间成为继续医学教育的最大供应商)的前总裁兼首席执行官。Physicians World于2000年被Thomson Healthcare收购。自2000至2003年担任Thomson Physicians World 的总裁。从2003年至2005年担任Thomson Medical Education的执行副总裁兼首席战略官。之后,成为Jobson Medical Information的执行副总裁和首席战略官。拥有44年的医疗行业经验,参与重要医药产品的推出例如Lipitorr,Actosr,Intron-Ar,Straterrar,Botoxr和Humirar。在Revlon Healthcare工作17年,担任各种国内和国际的医药营销的角色,包括市场营销国际业务部的副总裁。持有东南密苏里州立大学的理学士学位。
Martin E. Cearnal has served as a member of our Board of Directors since 2004. In 2008 he joined our management team to head commercial development for Cumberland, currently serving as Executive Vice President and Chief Commercial Officer. He is the former President and Chief Executive Officer of Physicians World, which became the largest provider of continuing medical education during his tenure from 1985 to 2000. Physicians World was acquired by Thomson Healthcare in 2000 and Mr. Cearnal served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. He then became Executive Vice President-Chief Strategy Officer for Jobson Medical Information. Mr. Cearnal has over 50 years of experience in the healthcare industry and has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox® and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles culminating in his position as Vice President, Marketing for International Operations. He has a B.S. degree from Southeast Missouri State University. - Martin E. Cearnal自2004年起一直担任我们的董事会成员。2008年他加入我们的管理团队,领导Cumberland的商业发展。目前担任高级副总裁兼首席商务官。他是Physicians World(1985至2000年在他任职期间成为继续医学教育的最大供应商)的前总裁兼首席执行官。Physicians World于2000年被Thomson Healthcare收购。自2000至2003年担任Thomson Physicians World 的总裁。从2003年至2005年担任Thomson Medical Education的执行副总裁兼首席战略官。之后,成为Jobson Medical Information的执行副总裁和首席战略官。拥有44年的医疗行业经验,参与重要医药产品的推出例如Lipitorr,Actosr,Intron-Ar,Straterrar,Botoxr和Humirar。在Revlon Healthcare工作17年,担任各种国内和国际的医药营销的角色,包括市场营销国际业务部的副总裁。持有东南密苏里州立大学的理学士学位。
- Martin E. Cearnal has served as a member of our Board of Directors since 2004. In 2008 he joined our management team to head commercial development for Cumberland, currently serving as Executive Vice President and Chief Commercial Officer. He is the former President and Chief Executive Officer of Physicians World, which became the largest provider of continuing medical education during his tenure from 1985 to 2000. Physicians World was acquired by Thomson Healthcare in 2000 and Mr. Cearnal served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. He then became Executive Vice President-Chief Strategy Officer for Jobson Medical Information. Mr. Cearnal has over 50 years of experience in the healthcare industry and has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox® and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles culminating in his position as Vice President, Marketing for International Operations. He has a B.S. degree from Southeast Missouri State University.
- Gordon R. Bernard
-
Gordon R. Bernard 自1999年至2010年担任我们的医疗总监,目前担任公司的顾问和医学顾问委员会主席。自2010年以来,一直担任我们的董事。他是范德比尔特大学的负责研究的协理副校长,也是医学Melinda Owen Bass Professor,过敏科、肺科和重病急救科的前任主任。此外,他是临床科学的高级副院长和范德比尔特的药房和治疗委员会的主席,负责审批批准范德比尔特医学中心的药物和治疗。自1980年以来,一直从事国家和国际的药品临床试验。自1994年成立以来,一直担任美国国立卫生研究院急性呼吸窘迫综合征临床试验网络的委员会的主席。这个网络是唯一得到联邦政府支持的,在医院的重症监护病房或加护病房进行持续性系统性的研究。持有西南路易斯安那大学的理学士学位和路易斯安那州立大学的医学博士学位。在范德比尔特的重症监护室工作, 第一手观察管理周围各种最严重患者的护理药品问题,并了解其未满足的医疗需求。
Gordon R. Bernard served as our Medical Director from 1999 until 2010 and currently serves as Chair of our Medical Advisory Board. He has served on our board of directors since 2010. Dr. Bernard is the Executive Vice President for Research at Vanderbilt University Medical Center, and also the Melinda Owen Bass Professor of Medicine and former Chief of the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt. In addition, he is Executive Vice President for Research, Senior Associate Dean for Clinical Sciences and Chairman of Vanderbilt’s Pharmacy and Therapeutics Committee, which is responsible for approving the Vanderbilt Medical Center Formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980 and he has been steering committee chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994 through its conclusion in 2014. This network is the only federally supported ongoing system for the conduct of research in the hospital Intensive Care Unit, or ICU. He holds a B.S. from the University of Southwestern Louisiana and an M.D. from Louisiana State University. Dr. Bernard maintains an active practice as an Intensivist in the Medical ICU at Vanderbilt and is therefore in a position to observe, first hand, the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs. - Gordon R. Bernard 自1999年至2010年担任我们的医疗总监,目前担任公司的顾问和医学顾问委员会主席。自2010年以来,一直担任我们的董事。他是范德比尔特大学的负责研究的协理副校长,也是医学Melinda Owen Bass Professor,过敏科、肺科和重病急救科的前任主任。此外,他是临床科学的高级副院长和范德比尔特的药房和治疗委员会的主席,负责审批批准范德比尔特医学中心的药物和治疗。自1980年以来,一直从事国家和国际的药品临床试验。自1994年成立以来,一直担任美国国立卫生研究院急性呼吸窘迫综合征临床试验网络的委员会的主席。这个网络是唯一得到联邦政府支持的,在医院的重症监护病房或加护病房进行持续性系统性的研究。持有西南路易斯安那大学的理学士学位和路易斯安那州立大学的医学博士学位。在范德比尔特的重症监护室工作, 第一手观察管理周围各种最严重患者的护理药品问题,并了解其未满足的医疗需求。
- Gordon R. Bernard served as our Medical Director from 1999 until 2010 and currently serves as Chair of our Medical Advisory Board. He has served on our board of directors since 2010. Dr. Bernard is the Executive Vice President for Research at Vanderbilt University Medical Center, and also the Melinda Owen Bass Professor of Medicine and former Chief of the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt. In addition, he is Executive Vice President for Research, Senior Associate Dean for Clinical Sciences and Chairman of Vanderbilt’s Pharmacy and Therapeutics Committee, which is responsible for approving the Vanderbilt Medical Center Formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980 and he has been steering committee chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994 through its conclusion in 2014. This network is the only federally supported ongoing system for the conduct of research in the hospital Intensive Care Unit, or ICU. He holds a B.S. from the University of Southwestern Louisiana and an M.D. from Louisiana State University. Dr. Bernard maintains an active practice as an Intensivist in the Medical ICU at Vanderbilt and is therefore in a position to observe, first hand, the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs.
高管简历
中英对照 |  中文 |  英文- Joseph C. Galante
Joseph C. Galante从1995年1月直到2010年7月退休担任索尼音乐(Sony Music)的董事会主席。他帮助阿拉巴马、柯林布雷克、肯尼·切斯尼、萨拉·埃文斯、戴夫·马休斯、武当派、SWV、贾德氏、孤星合唱团、玛蒂娜·麦克布莱德、K.T. Oslin、凯丽·皮克勒、凯莉·安德伍德、凯斯惠特利、克里斯杨和众多其他歌手开启演艺事业。他的领导力为诸如布鲁克斯和邓恩组合、艾伦·杰克逊、米兰达·兰伯特和布拉德·派斯利等超级明星的演艺事业提供了支撑。他担任美国乡村音乐协会(Country Music Association)、易洛魁资本(Iroquois Capital)、Artist Growth和Fishbowl Spirits的董事。他目前担任纳什维尔企业家中心的常驻导师。
Joseph C. Galante has served as a member of our Board of Directors since 2018. Mr. Galante is a music industry executive with extensive experience that scans a celebrated career. He is accredited with developing the careers of Alabama, Dave Mathews Band, Dolly Parton, Kenny Chesney, Brad Paisley, Martina McBride, Carrie Underwood, Clint Black, Miranda Lambert, and the Judds, among others. His successful business track record, entrepreneurial and public company experience make him a valuable member of our board. Mr. Galante began at RCA Records in New York, followed by a transfer to RCA Nashville where he served as a director at the label, followed by the role of Vice President of Promotion and Marketing. At the age of 32 he became the youngest person ever named to run a major country record label. In 1990 he was appointed President of RCA Records US based in New York. He returned to Nashville as Chairman to run the RCA and BNA labels in Nashville. Under his leadership, RCA Records was the number one country label for eleven consecutive years. He then served as Chairman of Sony Music Nashville for six years. He was presented with the Bob Kingsley Living Legend Award by the Opry Trust to honor his work for country music. Mr. Galante is currently a member of the Board of Directors of Pinnacle Financial Partners whose shares are listed on the Nasdaq stock exchange, the Country Music Association, and serves as the Chair of the CMA Foundation.- Joseph C. Galante从1995年1月直到2010年7月退休担任索尼音乐(Sony Music)的董事会主席。他帮助阿拉巴马、柯林布雷克、肯尼·切斯尼、萨拉·埃文斯、戴夫·马休斯、武当派、SWV、贾德氏、孤星合唱团、玛蒂娜·麦克布莱德、K.T. Oslin、凯丽·皮克勒、凯莉·安德伍德、凯斯惠特利、克里斯杨和众多其他歌手开启演艺事业。他的领导力为诸如布鲁克斯和邓恩组合、艾伦·杰克逊、米兰达·兰伯特和布拉德·派斯利等超级明星的演艺事业提供了支撑。他担任美国乡村音乐协会(Country Music Association)、易洛魁资本(Iroquois Capital)、Artist Growth和Fishbowl Spirits的董事。他目前担任纳什维尔企业家中心的常驻导师。
- Joseph C. Galante has served as a member of our Board of Directors since 2018. Mr. Galante is a music industry executive with extensive experience that scans a celebrated career. He is accredited with developing the careers of Alabama, Dave Mathews Band, Dolly Parton, Kenny Chesney, Brad Paisley, Martina McBride, Carrie Underwood, Clint Black, Miranda Lambert, and the Judds, among others. His successful business track record, entrepreneurial and public company experience make him a valuable member of our board. Mr. Galante began at RCA Records in New York, followed by a transfer to RCA Nashville where he served as a director at the label, followed by the role of Vice President of Promotion and Marketing. At the age of 32 he became the youngest person ever named to run a major country record label. In 1990 he was appointed President of RCA Records US based in New York. He returned to Nashville as Chairman to run the RCA and BNA labels in Nashville. Under his leadership, RCA Records was the number one country label for eleven consecutive years. He then served as Chairman of Sony Music Nashville for six years. He was presented with the Bob Kingsley Living Legend Award by the Opry Trust to honor his work for country music. Mr. Galante is currently a member of the Board of Directors of Pinnacle Financial Partners whose shares are listed on the Nasdaq stock exchange, the Country Music Association, and serves as the Chair of the CMA Foundation.
- Michael P. Bonner
MichaelP.Bonner获委任为高级财务及会计及首席财务官总监,自二零一六年二月一日起生效。Bonner先生自2013年1月起担任公司财务和税务报告总监,自2015年10月起职责扩大。Bonner先生拥有20年的财务和会计经验,主要是在医疗保健行业。加入Cumberland之前,他最近的职位是在Advocat Inc.(当时价值3亿美元的纳斯达克上市医疗保健供应商)担任会计和财务报告Vice President。此前,他曾担任LifePoint Health公司(当时纳斯达克上市的医疗保健供应商)的类似职务。Bonner先生在安永会计师事务所(Ernst&Young)的保证实践开始了他的职业生涯。Bonner先生是一名注册会计师,在特洛伊大学(Troy University)获得会计与工商管理理学学士学位和工商管理硕士学位,重点是会计学。
Michael P. Bonner was appointed as the Senior Director Finance and Accounting and Chief Financial Officer effective February 1 2016. Mr. Bonner had served as the Company’s Director, Financial and Tax Reporting since January 2013 with expanded responsibilities since October 2015. Mr. Bonner has 20 years of finance and accounting experience, primarily within the health care industry. Prior to joining Cumberland, his most recent position was at Advocat Inc. a then $300 million Nasdaq listed health care provider, as Vice President of Accounting and Financial Reporting. Prior to that, he had similar responsibilities at LifePoint Health, a then Nasdaq listed health care provider. Mr. Bonner started his career in the assurance practice at Ernst & Young. A Certified Public Accountant, Mr. Bonner has a Bachelor of Science in accounting and business administration and his MBA with an emphasis in accounting from Troy University.- MichaelP.Bonner获委任为高级财务及会计及首席财务官总监,自二零一六年二月一日起生效。Bonner先生自2013年1月起担任公司财务和税务报告总监,自2015年10月起职责扩大。Bonner先生拥有20年的财务和会计经验,主要是在医疗保健行业。加入Cumberland之前,他最近的职位是在Advocat Inc.(当时价值3亿美元的纳斯达克上市医疗保健供应商)担任会计和财务报告Vice President。此前,他曾担任LifePoint Health公司(当时纳斯达克上市的医疗保健供应商)的类似职务。Bonner先生在安永会计师事务所(Ernst&Young)的保证实践开始了他的职业生涯。Bonner先生是一名注册会计师,在特洛伊大学(Troy University)获得会计与工商管理理学学士学位和工商管理硕士学位,重点是会计学。
- Michael P. Bonner was appointed as the Senior Director Finance and Accounting and Chief Financial Officer effective February 1 2016. Mr. Bonner had served as the Company’s Director, Financial and Tax Reporting since January 2013 with expanded responsibilities since October 2015. Mr. Bonner has 20 years of finance and accounting experience, primarily within the health care industry. Prior to joining Cumberland, his most recent position was at Advocat Inc. a then $300 million Nasdaq listed health care provider, as Vice President of Accounting and Financial Reporting. Prior to that, he had similar responsibilities at LifePoint Health, a then Nasdaq listed health care provider. Mr. Bonner started his career in the assurance practice at Ernst & Young. A Certified Public Accountant, Mr. Bonner has a Bachelor of Science in accounting and business administration and his MBA with an emphasis in accounting from Troy University.
- Caroline R. Young
- 暂无中文简介
Caroline R. Young joined the Board of Directors of Cumberland Pharmaceuticals in 2016. Ms. Young was previously the President of the Nashville Health Care Council, a position she held from 2008 to 2015. Under her leadership, the Council’s membership grew to encompass 300 diverse organizations and launched the one-of-a-kind Fellows initiative designed to further the skills of business executives. Additionally, the Council’s innovative Leadership Health Care program expanded to consist of 1000 members. Ms. Young joined the Council in 2004 serving as vice president. Prior to the Council, Ms. Young was the founding Executive Director of Life Science Tennessee from 2002 to 2004. She also served in communications roles for the State of Tennessee’s Department of Economic and Community Development ECD from 1998 to 2002. Ms. Young most recently served as the Executive Director of NashvilleHealth, an initiative focused on improving the health of the citizens of Nashville-Davidson County. NashvilleHealth addresses area health equity issues and ensures Nashville continues to be a great place to live and work. Ms. Young has been recognized by the Nashville Business Journal as a “Healthcare Hero,” and the Nashville Medical News as a “Woman to Watch.” Currently, Ms. Young is a member of the Advisory Board of the Washington, DC-based Women Business Leaders of the U.S. Healthcare Industry. Ms. Young holds a B.A. from the University of Mississippi and a M.S. from the University of Tennessee. - 暂无中文简介
- Caroline R. Young joined the Board of Directors of Cumberland Pharmaceuticals in 2016. Ms. Young was previously the President of the Nashville Health Care Council, a position she held from 2008 to 2015. Under her leadership, the Council’s membership grew to encompass 300 diverse organizations and launched the one-of-a-kind Fellows initiative designed to further the skills of business executives. Additionally, the Council’s innovative Leadership Health Care program expanded to consist of 1000 members. Ms. Young joined the Council in 2004 serving as vice president. Prior to the Council, Ms. Young was the founding Executive Director of Life Science Tennessee from 2002 to 2004. She also served in communications roles for the State of Tennessee’s Department of Economic and Community Development ECD from 1998 to 2002. Ms. Young most recently served as the Executive Director of NashvilleHealth, an initiative focused on improving the health of the citizens of Nashville-Davidson County. NashvilleHealth addresses area health equity issues and ensures Nashville continues to be a great place to live and work. Ms. Young has been recognized by the Nashville Business Journal as a “Healthcare Hero,” and the Nashville Medical News as a “Woman to Watch.” Currently, Ms. Young is a member of the Advisory Board of the Washington, DC-based Women Business Leaders of the U.S. Healthcare Industry. Ms. Young holds a B.A. from the University of Mississippi and a M.S. from the University of Tennessee.
- Kenneth J. Krogulski
- 暂无中文简介
Kenneth J. Krogulski joined Cumberland’s Board of Directors in 2017. He has over 40 years of experience in security analysis and portfolio management and is currently the President and Chief Executive Officer of Berkshire Asset Management, LLC, as well as the company’s Chief Investment Officer. Berkshire is a 33-year-old independent SEC registered Pennsylvania based investment advisory firm with over $2.2 billion in assets under supervision. Prior to Berkshire, Mr. Krogulski began his career in financial services in 1979 at First Eastern Bank, N.A., now PNC Financial, as an investment analyst and portfolio manager, where he advanced to Chief Investment Officer of the Trust Department. He then joined Berkshire in 1990 and later led a management buy-out acquiring the company from Legg Mason. Under his leadership Berkshire’s assets under supervision have grown from $600 million in 2006 and are now over $2.2 billion. Currently Mr. Krogulski serves on the board of Allied Services Rehabilitation Hospital and is a Director of Landmark Community Bank LDKB: Nasdaq. Previously he served as the Director of the Wyoming Valley Health Care System, on the board of the F.M. Kirby Center for the Performing Arts, the Luzerne Foundation and on various other community boards. Mr. Krogulski holds a B.S. in finance from Indiana University of Pennsylvania and earned his M.B.A. from Wilkes University. In addition, he holds the Chartered Financial Analyst designation. - 暂无中文简介
- Kenneth J. Krogulski joined Cumberland’s Board of Directors in 2017. He has over 40 years of experience in security analysis and portfolio management and is currently the President and Chief Executive Officer of Berkshire Asset Management, LLC, as well as the company’s Chief Investment Officer. Berkshire is a 33-year-old independent SEC registered Pennsylvania based investment advisory firm with over $2.2 billion in assets under supervision. Prior to Berkshire, Mr. Krogulski began his career in financial services in 1979 at First Eastern Bank, N.A., now PNC Financial, as an investment analyst and portfolio manager, where he advanced to Chief Investment Officer of the Trust Department. He then joined Berkshire in 1990 and later led a management buy-out acquiring the company from Legg Mason. Under his leadership Berkshire’s assets under supervision have grown from $600 million in 2006 and are now over $2.2 billion. Currently Mr. Krogulski serves on the board of Allied Services Rehabilitation Hospital and is a Director of Landmark Community Bank LDKB: Nasdaq. Previously he served as the Director of the Wyoming Valley Health Care System, on the board of the F.M. Kirby Center for the Performing Arts, the Luzerne Foundation and on various other community boards. Mr. Krogulski holds a B.S. in finance from Indiana University of Pennsylvania and earned his M.B.A. from Wilkes University. In addition, he holds the Chartered Financial Analyst designation.
- Leo B. Pavliv
- 暂无中文简介
Leo B. Pavliv has served as our Vice President, Operations since 2003 was named Senior Vice President in 2009 and Chief Development Officer in 2012. He is responsible for Cumberland’s overall drug development, including manufacturing and quality operations, and has over 29 years of experience developing pharmaceutical and biological products. From 1997 to 2003 he worked at Cato Research, a contract research organization, most recently as Vice President of Pharmaceutical Development where he oversaw development of a wide variety of products throughout the development cycle. Prior to 1997 he held various scientific and management positions at both large pharmaceutical and smaller biopharmaceutical firms including Parke-Davis from 1984 to 1986 Agouron Pharmaceuticals from 1992 to 1997 ProCyte from 1989 to 1992 and Interferon Sciences from 1986 to 1989. He is a registered pharmacist R.Ph. and is regulatory affairs certified. Mr. Pavliv holds a B.S., Pharmacy, and an M.B.A. from Rutgers University. - 暂无中文简介
- Leo B. Pavliv has served as our Vice President, Operations since 2003 was named Senior Vice President in 2009 and Chief Development Officer in 2012. He is responsible for Cumberland’s overall drug development, including manufacturing and quality operations, and has over 29 years of experience developing pharmaceutical and biological products. From 1997 to 2003 he worked at Cato Research, a contract research organization, most recently as Vice President of Pharmaceutical Development where he oversaw development of a wide variety of products throughout the development cycle. Prior to 1997 he held various scientific and management positions at both large pharmaceutical and smaller biopharmaceutical firms including Parke-Davis from 1984 to 1986 Agouron Pharmaceuticals from 1992 to 1997 ProCyte from 1989 to 1992 and Interferon Sciences from 1986 to 1989. He is a registered pharmacist R.Ph. and is regulatory affairs certified. Mr. Pavliv holds a B.S., Pharmacy, and an M.B.A. from Rutgers University.
- Joey Jacobs
Joey Jacobs于2011年加盟Cumberland的董事会,并且是治理和提名委员会的成员。他在医疗业拥有超过35年的行业经验。目前担任Acadia医疗保健(一个快速成长的行为健康公司)的董事长兼首席执行官。 他是纳什维尔的Psychiatric Solutions, Inc.PSI的前任主席、总裁兼首席执行官,于1997年参与创办公司,在2010年公司出售给Universal Health Services之前,帮助公司发展成一个市值20亿美元的公司。在创办PSI之前,在Hospital Corporation of America HCA工作了21年,担任多个职位。除了担任纳什维尔卫生保健委员会的前任主席外,他也是美国医院联合会和精神病卫生系统全国协会的前任董事。目前,担任在范德比尔特的儿科医院Monroe Carel、AmSurg公司和心理健康管理的董事会成员。持有中田纳西州立大学的理学士学位。
Joey Jacobs joined Cumberland’s Board of Directors in 2011 and is Chairman of our Governance and Nominating Committee and Lead Independent Director. A healthcare veteran with more than 45 years of industry experience, Mr. Jacobs is the former Chairman and Chief Executive Officer of Acadia Healthcare, a rapidly growing behavioral health company. Mr. Jacobs is the former Chairman, President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. PSI, which he co-founded in 1997 and grew into a $2 billion behavioral healthcare system before the company’s sale to Universal Health Services in 2010. Prior to founding PSI, Mr. Jacobs spent 21 years at Hospital Corporation of America, or HCA, where he served in various capacities. In addition to serving as the former Chairman of the Nashville Health Care Council, he is also a past director of the Federation of American Hospitals, the National Association of Psychiatric Health Systems, Mental Health Management and Envision Corporation. He is currently a board member of the Monroe Carell, Jr. Children’s Hospital at Vanderbilt and Middle Tennesse State University. Mr. Jacobs holds a B.S. degree from Middle Tennessee State University.- Joey Jacobs于2011年加盟Cumberland的董事会,并且是治理和提名委员会的成员。他在医疗业拥有超过35年的行业经验。目前担任Acadia医疗保健(一个快速成长的行为健康公司)的董事长兼首席执行官。 他是纳什维尔的Psychiatric Solutions, Inc.PSI的前任主席、总裁兼首席执行官,于1997年参与创办公司,在2010年公司出售给Universal Health Services之前,帮助公司发展成一个市值20亿美元的公司。在创办PSI之前,在Hospital Corporation of America HCA工作了21年,担任多个职位。除了担任纳什维尔卫生保健委员会的前任主席外,他也是美国医院联合会和精神病卫生系统全国协会的前任董事。目前,担任在范德比尔特的儿科医院Monroe Carel、AmSurg公司和心理健康管理的董事会成员。持有中田纳西州立大学的理学士学位。
- Joey Jacobs joined Cumberland’s Board of Directors in 2011 and is Chairman of our Governance and Nominating Committee and Lead Independent Director. A healthcare veteran with more than 45 years of industry experience, Mr. Jacobs is the former Chairman and Chief Executive Officer of Acadia Healthcare, a rapidly growing behavioral health company. Mr. Jacobs is the former Chairman, President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc. PSI, which he co-founded in 1997 and grew into a $2 billion behavioral healthcare system before the company’s sale to Universal Health Services in 2010. Prior to founding PSI, Mr. Jacobs spent 21 years at Hospital Corporation of America, or HCA, where he served in various capacities. In addition to serving as the former Chairman of the Nashville Health Care Council, he is also a past director of the Federation of American Hospitals, the National Association of Psychiatric Health Systems, Mental Health Management and Envision Corporation. He is currently a board member of the Monroe Carell, Jr. Children’s Hospital at Vanderbilt and Middle Tennesse State University. Mr. Jacobs holds a B.S. degree from Middle Tennessee State University.
- Jonathan Griggs
Jonathan Griggs自2010年以来担任本公司董事会的一员,是我们的审计、薪酬和治理与提名委员会的成员。他的职业生涯中,在制药和生物技术行业工作超过40年,包括许多国际经验。在Warner Lambert Corporation工作23年,担任许多要职,最高任职是人力资源副总裁。在此期间,成功的领导了三家医药企业整合成为当时最大的企业Parke Davis。从1992年至今,一直担任Griggs & Associates(管理和人力资源咨询公司,协助创业公司和提供周转情况下的危急援助)的首席执行官。在 AACA Antique Auto Club of America Museum(领先的交通博物馆)的成立过程中,提供领导和战略管理,曾担任董事长,现任董事。持有宾夕法尼亚州立大学的理学士学位和宾夕法尼亚大学沃顿商学院的管理硕士学位。他一直是Cumberland Pharmaceuticals的顾问。自1999年公司开始运作起,担任医药顾问委员会的成员。
Jonathan Griggs has served as a member of our Board of Directors since 2010. Mr. Griggs has elected to retire at the end of this term and will not stand for re-election at the Annual Meeting. His career spans more than 41 years in the pharmaceutical and biotechnology industries and includes significant international experience. He spent 23 years at Warner Lambert Corporation in positions of increasing responsibility, culminating with his position as Vice President of Human Resources. During his tenure with Warner Lambert, he provided leadership for the successful integration of three pharmaceutical businesses into what became Parke Davis, the largest consolidation in the industry at that time. From 1992 to present he has been the CEO of Griggs & Associates, a management and human resources consulting firm assisting start-up companies and providing critical assistance in turnaround situations. Mr. Griggs also provided the leadership and strategic management for the formation and establishment of the AACA Antique Auto Club of America Museum, a leading transportation museum where he served as chairman and is currently a director. Mr. Griggs has his B.S. Degree from Penn State and attended the Wharton School of Management at the University of Pennsylvania. He has been an advisor to Cumberland Pharmaceuticals as a member of the company’s Pharmaceutical Advisory Board since it began operations in 1999.- Jonathan Griggs自2010年以来担任本公司董事会的一员,是我们的审计、薪酬和治理与提名委员会的成员。他的职业生涯中,在制药和生物技术行业工作超过40年,包括许多国际经验。在Warner Lambert Corporation工作23年,担任许多要职,最高任职是人力资源副总裁。在此期间,成功的领导了三家医药企业整合成为当时最大的企业Parke Davis。从1992年至今,一直担任Griggs & Associates(管理和人力资源咨询公司,协助创业公司和提供周转情况下的危急援助)的首席执行官。在 AACA Antique Auto Club of America Museum(领先的交通博物馆)的成立过程中,提供领导和战略管理,曾担任董事长,现任董事。持有宾夕法尼亚州立大学的理学士学位和宾夕法尼亚大学沃顿商学院的管理硕士学位。他一直是Cumberland Pharmaceuticals的顾问。自1999年公司开始运作起,担任医药顾问委员会的成员。
- Jonathan Griggs has served as a member of our Board of Directors since 2010. Mr. Griggs has elected to retire at the end of this term and will not stand for re-election at the Annual Meeting. His career spans more than 41 years in the pharmaceutical and biotechnology industries and includes significant international experience. He spent 23 years at Warner Lambert Corporation in positions of increasing responsibility, culminating with his position as Vice President of Human Resources. During his tenure with Warner Lambert, he provided leadership for the successful integration of three pharmaceutical businesses into what became Parke Davis, the largest consolidation in the industry at that time. From 1992 to present he has been the CEO of Griggs & Associates, a management and human resources consulting firm assisting start-up companies and providing critical assistance in turnaround situations. Mr. Griggs also provided the leadership and strategic management for the formation and establishment of the AACA Antique Auto Club of America Museum, a leading transportation museum where he served as chairman and is currently a director. Mr. Griggs has his B.S. Degree from Penn State and attended the Wharton School of Management at the University of Pennsylvania. He has been an advisor to Cumberland Pharmaceuticals as a member of the company’s Pharmaceutical Advisory Board since it began operations in 1999.
- James R. Jones
James R. Jones自2010年起一直担任我们的董事会成员。在毕马威会计师事务所作为专业会计度过了35年的职业生涯,包括从1999年到2006年担任在田纳西州纳什维尔办公室的管理合伙人。他曾在毕马威担任各种职位,其中包括在杰克逊、密西西比、华盛顿特区和格林维尔、南卡罗来纳州的办公室。任职于毕马威会计师事务所期间,率领100多人向庞大客户群提供会计服务。2006年退休之后,曾担任顾问,并提供给多家公司各种咨询服务,包括管理长期护理机构的董事会和担任慈善机构的临时行政总裁。他是在范德堡大学欧文研究生院的一位兼职教师。目前,他是田纳西Argent Trust Company的董事和审核委员会委员。亦担任本公司审核委员会主席,和委员会的财务专家。持有密西西比学院的理学士学位和密西西比州立大学的工商管理硕士学位。
James R. Jones has served as a member of our Board of Directors since 2010 and is Chair of our Audit Committee. Mr. Jones’ 36 year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in various capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, D.C. and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an extensive client base. Following retirement in 2006 he has served as an advisor as well as provided various consulting services to several companies, including acting as liaison between management and the board of directors of a long-term care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committees of Argent Trust Company of Tennessee and Belmont University. Mr. Jones also serves as a member of our Audit Committee and is our Audit Committee financial expert. Mr. Jones holds a B.S. from Mississippi College and an M.B.A from Mississippi State University.- James R. Jones自2010年起一直担任我们的董事会成员。在毕马威会计师事务所作为专业会计度过了35年的职业生涯,包括从1999年到2006年担任在田纳西州纳什维尔办公室的管理合伙人。他曾在毕马威担任各种职位,其中包括在杰克逊、密西西比、华盛顿特区和格林维尔、南卡罗来纳州的办公室。任职于毕马威会计师事务所期间,率领100多人向庞大客户群提供会计服务。2006年退休之后,曾担任顾问,并提供给多家公司各种咨询服务,包括管理长期护理机构的董事会和担任慈善机构的临时行政总裁。他是在范德堡大学欧文研究生院的一位兼职教师。目前,他是田纳西Argent Trust Company的董事和审核委员会委员。亦担任本公司审核委员会主席,和委员会的财务专家。持有密西西比学院的理学士学位和密西西比州立大学的工商管理硕士学位。
- James R. Jones has served as a member of our Board of Directors since 2010 and is Chair of our Audit Committee. Mr. Jones’ 36 year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in various capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, D.C. and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an extensive client base. Following retirement in 2006 he has served as an advisor as well as provided various consulting services to several companies, including acting as liaison between management and the board of directors of a long-term care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committees of Argent Trust Company of Tennessee and Belmont University. Mr. Jones also serves as a member of our Audit Committee and is our Audit Committee financial expert. Mr. Jones holds a B.S. from Mississippi College and an M.B.A from Mississippi State University.
- A.J. Kazimi
A.J. Kazimi于1999年创办本公司。自成立以来,一直担任公司董事会主席及行政总裁。他的职业生涯包括在生物制药行业的25年。在加入本公司前,帮助创立Therapeutic Antibodies Inc.(一家国际生物制药公司),长达11年。作为总裁兼首席运营官,从公司的起步到首次公开募股,他为公司的增长做出了突出的贡献。 监督三个国家的业务,亲自参与公司的产品开发战略、批准、许可协议和超过1亿美元的股权和债务融资筹集。在这之前,曾在Brown-Forman公司担任一系列的管理职位,并帮助推出多款新产品。 曾服务于纳什维尔保健委员会(美国最大医疗保健公司的行业协会)和Aegis Toxicology Sciences公司(由联邦政府认证的法医毒物实验室)的董事会。他还担任CET的主席及行政总裁。持有巴黎圣母院的理学士学位和范德堡大学欧文研究生院的MBA管理学位。
A.J. Kazimi founded our company in 1999 and has served as the Chairman of our Board of Directors and Chief Executive Officer since inception. His career includes 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of the company's Acetadote and Caldolor brands, while also leading the acquisition of the Company's five other commercial products. He was responsible for Cumberland's initial public offering and listing on the Nasdaq stock exchange. He also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies. Prior to joining our company, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company's growth from its start-up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions and helping to launch several new products. Mr. Kazimi serves on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. He also serves on the Boards of the Tennessee Historical Society and the Gettysburg Foundation which partners with the National Park Service to preserve the historic military park. Mr. Kazimi is a member of the Board of Visitors at the Vanderbilt University Business School and the Visiting Committee at the Loyola University New Orleans' College of Business. He previously served on the board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors. He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt University Owen Graduate School of Management.- A.J. Kazimi于1999年创办本公司。自成立以来,一直担任公司董事会主席及行政总裁。他的职业生涯包括在生物制药行业的25年。在加入本公司前,帮助创立Therapeutic Antibodies Inc.(一家国际生物制药公司),长达11年。作为总裁兼首席运营官,从公司的起步到首次公开募股,他为公司的增长做出了突出的贡献。 监督三个国家的业务,亲自参与公司的产品开发战略、批准、许可协议和超过1亿美元的股权和债务融资筹集。在这之前,曾在Brown-Forman公司担任一系列的管理职位,并帮助推出多款新产品。 曾服务于纳什维尔保健委员会(美国最大医疗保健公司的行业协会)和Aegis Toxicology Sciences公司(由联邦政府认证的法医毒物实验室)的董事会。他还担任CET的主席及行政总裁。持有巴黎圣母院的理学士学位和范德堡大学欧文研究生院的MBA管理学位。
- A.J. Kazimi founded our company in 1999 and has served as the Chairman of our Board of Directors and Chief Executive Officer since inception. His career includes 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of the company's Acetadote and Caldolor brands, while also leading the acquisition of the Company's five other commercial products. He was responsible for Cumberland's initial public offering and listing on the Nasdaq stock exchange. He also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies. Prior to joining our company, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company's growth from its start-up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions and helping to launch several new products. Mr. Kazimi serves on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. He also serves on the Boards of the Tennessee Historical Society and the Gettysburg Foundation which partners with the National Park Service to preserve the historic military park. Mr. Kazimi is a member of the Board of Visitors at the Vanderbilt University Business School and the Visiting Committee at the Loyola University New Orleans' College of Business. He previously served on the board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors. He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt University Owen Graduate School of Management.
- Martin E. Cearnal
Martin E. Cearnal自2004年起一直担任我们的董事会成员。2008年他加入我们的管理团队,领导Cumberland的商业发展。目前担任高级副总裁兼首席商务官。他是Physicians World(1985至2000年在他任职期间成为继续医学教育的最大供应商)的前总裁兼首席执行官。Physicians World于2000年被Thomson Healthcare收购。自2000至2003年担任Thomson Physicians World 的总裁。从2003年至2005年担任Thomson Medical Education的执行副总裁兼首席战略官。之后,成为Jobson Medical Information的执行副总裁和首席战略官。拥有44年的医疗行业经验,参与重要医药产品的推出例如Lipitorr,Actosr,Intron-Ar,Straterrar,Botoxr和Humirar。在Revlon Healthcare工作17年,担任各种国内和国际的医药营销的角色,包括市场营销国际业务部的副总裁。持有东南密苏里州立大学的理学士学位。
Martin E. Cearnal has served as a member of our Board of Directors since 2004. In 2008 he joined our management team to head commercial development for Cumberland, currently serving as Executive Vice President and Chief Commercial Officer. He is the former President and Chief Executive Officer of Physicians World, which became the largest provider of continuing medical education during his tenure from 1985 to 2000. Physicians World was acquired by Thomson Healthcare in 2000 and Mr. Cearnal served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. He then became Executive Vice President-Chief Strategy Officer for Jobson Medical Information. Mr. Cearnal has over 50 years of experience in the healthcare industry and has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox® and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles culminating in his position as Vice President, Marketing for International Operations. He has a B.S. degree from Southeast Missouri State University.- Martin E. Cearnal自2004年起一直担任我们的董事会成员。2008年他加入我们的管理团队,领导Cumberland的商业发展。目前担任高级副总裁兼首席商务官。他是Physicians World(1985至2000年在他任职期间成为继续医学教育的最大供应商)的前总裁兼首席执行官。Physicians World于2000年被Thomson Healthcare收购。自2000至2003年担任Thomson Physicians World 的总裁。从2003年至2005年担任Thomson Medical Education的执行副总裁兼首席战略官。之后,成为Jobson Medical Information的执行副总裁和首席战略官。拥有44年的医疗行业经验,参与重要医药产品的推出例如Lipitorr,Actosr,Intron-Ar,Straterrar,Botoxr和Humirar。在Revlon Healthcare工作17年,担任各种国内和国际的医药营销的角色,包括市场营销国际业务部的副总裁。持有东南密苏里州立大学的理学士学位。
- Martin E. Cearnal has served as a member of our Board of Directors since 2004. In 2008 he joined our management team to head commercial development for Cumberland, currently serving as Executive Vice President and Chief Commercial Officer. He is the former President and Chief Executive Officer of Physicians World, which became the largest provider of continuing medical education during his tenure from 1985 to 2000. Physicians World was acquired by Thomson Healthcare in 2000 and Mr. Cearnal served as President of Thomson Physicians World from 2000 to 2003 and Executive Vice President-Chief Strategy Officer for Thomson Medical Education from 2003 through 2005. He then became Executive Vice President-Chief Strategy Officer for Jobson Medical Information. Mr. Cearnal has over 50 years of experience in the healthcare industry and has been involved with the launches of such noteworthy pharmaceutical products as Lipitor®, Actos®, Intron-A®, Straterra®, Botox® and Humira®. He spent 17 years at Revlon Healthcare in a variety of domestic and international pharmaceutical marketing roles culminating in his position as Vice President, Marketing for International Operations. He has a B.S. degree from Southeast Missouri State University.
- Gordon R. Bernard
Gordon R. Bernard 自1999年至2010年担任我们的医疗总监,目前担任公司的顾问和医学顾问委员会主席。自2010年以来,一直担任我们的董事。他是范德比尔特大学的负责研究的协理副校长,也是医学Melinda Owen Bass Professor,过敏科、肺科和重病急救科的前任主任。此外,他是临床科学的高级副院长和范德比尔特的药房和治疗委员会的主席,负责审批批准范德比尔特医学中心的药物和治疗。自1980年以来,一直从事国家和国际的药品临床试验。自1994年成立以来,一直担任美国国立卫生研究院急性呼吸窘迫综合征临床试验网络的委员会的主席。这个网络是唯一得到联邦政府支持的,在医院的重症监护病房或加护病房进行持续性系统性的研究。持有西南路易斯安那大学的理学士学位和路易斯安那州立大学的医学博士学位。在范德比尔特的重症监护室工作, 第一手观察管理周围各种最严重患者的护理药品问题,并了解其未满足的医疗需求。
Gordon R. Bernard served as our Medical Director from 1999 until 2010 and currently serves as Chair of our Medical Advisory Board. He has served on our board of directors since 2010. Dr. Bernard is the Executive Vice President for Research at Vanderbilt University Medical Center, and also the Melinda Owen Bass Professor of Medicine and former Chief of the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt. In addition, he is Executive Vice President for Research, Senior Associate Dean for Clinical Sciences and Chairman of Vanderbilt’s Pharmacy and Therapeutics Committee, which is responsible for approving the Vanderbilt Medical Center Formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980 and he has been steering committee chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994 through its conclusion in 2014. This network is the only federally supported ongoing system for the conduct of research in the hospital Intensive Care Unit, or ICU. He holds a B.S. from the University of Southwestern Louisiana and an M.D. from Louisiana State University. Dr. Bernard maintains an active practice as an Intensivist in the Medical ICU at Vanderbilt and is therefore in a position to observe, first hand, the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs.- Gordon R. Bernard 自1999年至2010年担任我们的医疗总监,目前担任公司的顾问和医学顾问委员会主席。自2010年以来,一直担任我们的董事。他是范德比尔特大学的负责研究的协理副校长,也是医学Melinda Owen Bass Professor,过敏科、肺科和重病急救科的前任主任。此外,他是临床科学的高级副院长和范德比尔特的药房和治疗委员会的主席,负责审批批准范德比尔特医学中心的药物和治疗。自1980年以来,一直从事国家和国际的药品临床试验。自1994年成立以来,一直担任美国国立卫生研究院急性呼吸窘迫综合征临床试验网络的委员会的主席。这个网络是唯一得到联邦政府支持的,在医院的重症监护病房或加护病房进行持续性系统性的研究。持有西南路易斯安那大学的理学士学位和路易斯安那州立大学的医学博士学位。在范德比尔特的重症监护室工作, 第一手观察管理周围各种最严重患者的护理药品问题,并了解其未满足的医疗需求。
- Gordon R. Bernard served as our Medical Director from 1999 until 2010 and currently serves as Chair of our Medical Advisory Board. He has served on our board of directors since 2010. Dr. Bernard is the Executive Vice President for Research at Vanderbilt University Medical Center, and also the Melinda Owen Bass Professor of Medicine and former Chief of the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt. In addition, he is Executive Vice President for Research, Senior Associate Dean for Clinical Sciences and Chairman of Vanderbilt’s Pharmacy and Therapeutics Committee, which is responsible for approving the Vanderbilt Medical Center Formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980 and he has been steering committee chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994 through its conclusion in 2014. This network is the only federally supported ongoing system for the conduct of research in the hospital Intensive Care Unit, or ICU. He holds a B.S. from the University of Southwestern Louisiana and an M.D. from Louisiana State University. Dr. Bernard maintains an active practice as an Intensivist in the Medical ICU at Vanderbilt and is therefore in a position to observe, first hand, the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs.
- Leo Pavliv
Leo Pavliv自2003年起被任命为负责运营的副总裁。2009年担任高级副总裁。2012年担任首席开发官。负责Cumberland的整体药物开发,包括生产和质量运营,在开发医药和生物制品方面拥有超过25年的经验。从1997年到2003年,曾在Cato Research(一个合同研究组织)工作,最后担任医药产业发展的副总裁,在整个开发周期中负责种类繁多的产品开发。在1997年之前,在大型和小型制药公司担任过各种科学和管理职位,包括自1984年至1986年Parke-Davis,自1992年至1997年Agouron公司制药,自1989年至1992年ProCyte和自1986年至1989年Interferon Sciences。他是一名注册药剂师,获得监管事务的认证。持有Pharmacy的学士学位,以及罗格斯大学的MBA学位。
Leo Pavliv has served as our Vice President, Operations since 2003 was named Senior Vice President in 2009 and Chief Development Officer in 2012. He is responsible for Cumberland's overall drug development, including manufacturing and quality operations, and has over 29 years of experience developing pharmaceutical and biological products. From 1997 to 2003 he worked at Cato Research, a contract research organization, most recently as Vice President of Pharmaceutical Development where he oversaw development of a wide variety of products throughout the development cycle. Prior to 1997 he held various scientific and management positions at both large pharmaceutical and smaller biopharmaceutical firms including Parke-Davis from 1984 to 1986 Agouron Pharmaceuticals from 1992 to 1997 ProCyte from 1989 to 1992 and Interferon Sciences from 1986 to 1989. He is a registered pharmacist R.Ph. and is regulatory affairs certified. Mr. Pavliv holds a B.S., Pharmacy, and an M.B.A. from Rutgers University.- Leo Pavliv自2003年起被任命为负责运营的副总裁。2009年担任高级副总裁。2012年担任首席开发官。负责Cumberland的整体药物开发,包括生产和质量运营,在开发医药和生物制品方面拥有超过25年的经验。从1997年到2003年,曾在Cato Research(一个合同研究组织)工作,最后担任医药产业发展的副总裁,在整个开发周期中负责种类繁多的产品开发。在1997年之前,在大型和小型制药公司担任过各种科学和管理职位,包括自1984年至1986年Parke-Davis,自1992年至1997年Agouron公司制药,自1989年至1992年ProCyte和自1986年至1989年Interferon Sciences。他是一名注册药剂师,获得监管事务的认证。持有Pharmacy的学士学位,以及罗格斯大学的MBA学位。
- Leo Pavliv has served as our Vice President, Operations since 2003 was named Senior Vice President in 2009 and Chief Development Officer in 2012. He is responsible for Cumberland's overall drug development, including manufacturing and quality operations, and has over 29 years of experience developing pharmaceutical and biological products. From 1997 to 2003 he worked at Cato Research, a contract research organization, most recently as Vice President of Pharmaceutical Development where he oversaw development of a wide variety of products throughout the development cycle. Prior to 1997 he held various scientific and management positions at both large pharmaceutical and smaller biopharmaceutical firms including Parke-Davis from 1984 to 1986 Agouron Pharmaceuticals from 1992 to 1997 ProCyte from 1989 to 1992 and Interferon Sciences from 1986 to 1989. He is a registered pharmacist R.Ph. and is regulatory affairs certified. Mr. Pavliv holds a B.S., Pharmacy, and an M.B.A. from Rutgers University.
- James L. Herman
James L. Herman处理所有国民经济核算的销售,包括批发和零售连锁企业采购办事处、管理式医疗家庭办公室和联邦政府账户。他还负责监督本公司的合规工作。自2003年以来在本公司工作,有20年的制药行业经验。从1998年到2003年,在Solvay制药公司担任管理式医疗主任和贸易事务与客户服务主任。从1990年至1998年在Schwarz制药担任国民核算和管理式医疗的全国销售领导职务的。持有印第安那大学的理学士学位和Cardinal Stritch大学的工商管理硕士学位。
James L. Herman handles all national accounts sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He is also charged with overseeing our corporate compliance efforts. He has been with us since 2003 and has 31 years of pharmaceutical industry experience. From 1998 to 2003 he was with Solvay Pharmaceuticals and served as Director of Managed Care and Director of Trade Affairs and Customer Service. From 1990 to 1998 Mr. Herman was with Schwarz Pharma, where he held national sales leadership positions in National Accounts and Managed Care. He holds a B.S. from Indiana University and an M.B.A. from Cardinal Stritch University.- James L. Herman处理所有国民经济核算的销售,包括批发和零售连锁企业采购办事处、管理式医疗家庭办公室和联邦政府账户。他还负责监督本公司的合规工作。自2003年以来在本公司工作,有20年的制药行业经验。从1998年到2003年,在Solvay制药公司担任管理式医疗主任和贸易事务与客户服务主任。从1990年至1998年在Schwarz制药担任国民核算和管理式医疗的全国销售领导职务的。持有印第安那大学的理学士学位和Cardinal Stritch大学的工商管理硕士学位。
- James L. Herman handles all national accounts sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He is also charged with overseeing our corporate compliance efforts. He has been with us since 2003 and has 31 years of pharmaceutical industry experience. From 1998 to 2003 he was with Solvay Pharmaceuticals and served as Director of Managed Care and Director of Trade Affairs and Customer Service. From 1990 to 1998 Mr. Herman was with Schwarz Pharma, where he held national sales leadership positions in National Accounts and Managed Care. He holds a B.S. from Indiana University and an M.B.A. from Cardinal Stritch University.